- Home
- OGI vs DMAC Comparison
OGI vs DMAC Comparison
Compare OGI & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGI
- DMAC
- Stock Information
- Founded
- OGI 2013
- DMAC 2000
- Country
- OGI Canada
- DMAC United States
- Employees
- OGI N/A
- DMAC N/A
- Industry
- OGI Biotechnology: Pharmaceutical Preparations
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- OGI Health Care
- DMAC Health Care
- Exchange
- OGI Nasdaq
- DMAC Nasdaq
- Market Cap
- OGI 186.1M
- DMAC 178.0M
- IPO Year
- OGI N/A
- DMAC N/A
- Fundamental
- Price
- OGI $1.53
- DMAC $5.05
- Analyst Decision
- OGI
- DMAC Strong Buy
- Analyst Count
- OGI 0
- DMAC 4
- Target Price
- OGI N/A
- DMAC $10.75
- AVG Volume (30 Days)
- OGI 599.7K
- DMAC 494.3K
- Earning Date
- OGI 08-12-2025
- DMAC 08-06-2025
- Dividend Yield
- OGI N/A
- DMAC N/A
- EPS Growth
- OGI N/A
- DMAC N/A
- EPS
- OGI 0.10
- DMAC N/A
- Revenue
- OGI $135,031,829.00
- DMAC N/A
- Revenue This Year
- OGI $50.30
- DMAC N/A
- Revenue Next Year
- OGI $16.01
- DMAC N/A
- P/E Ratio
- OGI $14.76
- DMAC N/A
- Revenue Growth
- OGI 20.49
- DMAC N/A
- 52 Week Low
- OGI $0.85
- DMAC $3.19
- 52 Week High
- OGI $2.08
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- OGI 61.28
- DMAC 66.86
- Support Level
- OGI $1.43
- DMAC $3.65
- Resistance Level
- OGI $1.59
- DMAC $5.25
- Average True Range (ATR)
- OGI 0.06
- DMAC 0.42
- MACD
- OGI 0.01
- DMAC 0.14
- Stochastic Oscillator
- OGI 75.56
- DMAC 88.06
About OGI Organigram Holdings Inc.
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.